These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 22993159)

  • 1. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.
    Potter JA; Owsianka AM; Jeffery N; Matthews DJ; Keck ZY; Lau P; Foung SK; Taylor GL; Patel AH
    J Virol; 2012 Dec; 86(23):12923-32. PubMed ID: 22993159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.
    Li Y; Pierce BG; Wang Q; Keck ZY; Fuerst TR; Foung SK; Mariuzza RA
    J Biol Chem; 2015 Apr; 290(16):10117-25. PubMed ID: 25737449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.
    Tarr AW; Owsianka AM; Timms JM; McClure CP; Brown RJ; Hickling TP; Pietschmann T; Bartenschlager R; Patel AH; Ball JK
    Hepatology; 2006 Mar; 43(3):592-601. PubMed ID: 16496330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
    Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
    mBio; 2017 May; 8(3):. PubMed ID: 28512091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
    Khera T; Behrendt P; Bankwitz D; Brown RJP; Todt D; Doepke M; Khan AG; Schulze K; Law J; Logan M; Hockman D; Wong JAJ; Dold L; Gonzalez-Motos V; Spengler U; Viejo-Borbolla A; Ströh LJ; Krey T; Tarr AW; Steinmann E; Manns MP; Klein F; Guzman CA; Marcotrigiano J; Houghton M; Pietschmann T
    J Hepatol; 2019 Apr; 70(4):593-602. PubMed ID: 30439392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422.
    Sandomenico A; Leonardi A; Berisio R; Sanguigno L; Focà G; Focà A; Ruggiero A; Doti N; Muscariello L; Barone D; Farina C; Owsianka A; Vitagliano L; Patel AH; Ruvo M
    J Virol; 2016 Jan; 90(7):3745-59. PubMed ID: 26819303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33.
    Kong L; Giang E; Nieusma T; Robbins JB; Deller MC; Stanfield RL; Wilson IA; Law M
    J Virol; 2012 Dec; 86(23):13085-8. PubMed ID: 22973046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.
    Tarr AW; Owsianka AM; Jayaraj D; Brown RJP; Hickling TP; Irving WL; Patel AH; Ball JK
    J Gen Virol; 2007 Nov; 88(Pt 11):2991-3001. PubMed ID: 17947521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.
    Meola A; Tarr AW; England P; Meredith LW; McClure CP; Foung SK; McKeating JA; Ball JK; Rey FA; Krey T
    J Virol; 2015 Feb; 89(4):2170-81. PubMed ID: 25473061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
    Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies.
    Pantua H; Diao J; Ultsch M; Hazen M; Mathieu M; McCutcheon K; Takeda K; Date S; Cheung TK; Phung Q; Hass P; Arnott D; Hongo JA; Matthews DJ; Brown A; Patel AH; Kelley RF; Eigenbrot C; Kapadia SB
    J Mol Biol; 2013 Jun; 425(11):1899-1914. PubMed ID: 23458406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope.
    Pierce BG; Boucher EN; Piepenbrink KH; Ejemel M; Rapp CA; Thomas WD; Sundberg EJ; Weng Z; Wang Y
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.
    Giang E; Dorner M; Prentoe JC; Dreux M; Evans MJ; Bukh J; Rice CM; Ploss A; Burton DR; Law M
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6205-10. PubMed ID: 22492964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
    Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK
    PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
    McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE
    J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.